Zydus Cadila to launch anti-obesity drug Slimona in India

RELATED NEWS Zydus Cadila's net profit up by whopping 53% in FY07 Zydus receives approval for Losartan Potassium tablets Zydus Cadila acquires Nippon Universal Nifty BSE | NSE 30/05/12 Are Mutual Funds betting on Nifty?

It works by blocking the neuronal CB1 receptors, thereby decreasing the activity of the endocannabinoid system (EC system). These CB1 receptors when activated by the endocannabinoids such as anandamide, increases one's appetite, which is likely to lead to obesity. The EC System regulates food intake and energy balance. It also improves the body's lipid and glucose metabolism. Trials have shown significant reduction in weight and waist circumference i.e. abdominal obesity.

Efficacy and safety in the long-term use is an important feature of any anti-obesity drug. Rimonabant also had a significant impact on metabolic CVD risk factors, greater than that expected by weight loss alone. The group has already begun introducing Slimona to the medical fraternity through Medical Conferences and Continuous Medical Education (CME) initiatives. The drug is priced economically at a rate of Rs. 5.50 per tablet, making it economical to a wide patient group. Emphasizing this point, Mr. Ashok Bhatia, Senior Vice-President (BU-7), Zydus Cadila says: 'The price of Slimona, has been thoughtfully fixed to benefit the large patient population in all classes. We will harness the full thrust of the Zydus Marketing teams to ensure that this vitally needed drug is available to doctors across the country - even in smaller cities and towns'.

The introduction of Slimona will boost the group's presence in the Chronic care segment. Zydus Cadila currently markets products in cardiology, diabetology and neurology segments strengthening the Chronic care portfolio and ranks the No. 1 CVS player in the participated segment. The group's leading brands in the chronic care segment include Aten, Atorva, Depin and Amlodac.

 

Sourced From: Pressman India